Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization.
On the company’s earnings call, President and CEO Helen Torley said Halozyme “started 2026 with exceptional momentum,” citing the performance of approved partner products, recent licensing deals and an expanding clinical pipeline. Interim Chief Financial Officer David Ramsay said the company’s first-quarter performance reflected “robust year-over-year royalty growth” and reinforced the operating leverage of Halozyme’s royalty-driven business model.
